Table 2 Landmark analysis of outcomes of interest at multiple temporal points post-transplant: comparison of SGLT-2i users versus non-users

From: The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients

Outcome

aHR (95% CI)

p valuea

Usage of SGLT-2i within the 2 weeks post-transplant

 All-cause mortality

0.35 [0.25−0.49]

<0.001

 MACE

0.55 [0.44−0.69]

<0.001

 MAKE

0.65 [0.57−0.75]

<0.001

Usage of SGLT-2i within the 4 weeks post-transplant

 All-cause mortality

0.31 [0.23−0.41]

<0.001

 MACE

0.53 [0.43−0.65]

<0.001

 MAKE

0.56 [0.50−0.64]

<0.001

Usage of SGLT-2i within the 6 weeks post-transplant

 All-cause mortality

0.68 [0.51−0.90]

0.007

 MACE

0.60 [0.46−0.77]

<0.001

 MAKE

0.67 [0.57−0.79]

<0.001

Usage of SGLT-2i within the 2 months post-transplant

 All-cause mortality

0.47 [0.35−0.63]

<0.001

 MACE

0.58 [0.45−0.75]

<0.001

 MAKE

0.56 [0.47−0.66]

<0.001

Usage of SGLT-2i within the 6 months post-transplant

 All-cause mortality

0.32 [0.22−0.47]

<0.001

 MACE

0.58 [0.45−0.74]

<0.001

 MAKE

0.50 [0.42−0.59]

<0.001

Usage of SGLT-2i within the 12 months post-transplant

 All-cause mortality

0.36 [0.23−0.56]

<0.001

 MACE

0.65 [0.50−0.84]

<0.001

 MAKE

0.53 [0.45−0.64]

<0.001

  1. aThe log-rank test was used to assess differences in outcome probabilities between cohorts, with significance determined at a two-sided p value < 0.05.
  2. aHR adjusted hazard ratio, CI confidence interval, MACE major adverse cardiovascular event, MAKE major adverse kidney event, SGLT-2i sodium-glucose cotransporter 2 inhibitor.
Back to article page